Barclays Downgrades Charles River Labs (CRL) to Equal Weight
CRL Hot Sheet
Rating Summary:2 Buy, 8 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 16 | New: 82
Barclays downgrades Charles River Labs (NYSE: CRL) from Overweight to Equal Weight, while maintaining their $36 price target.
Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services.
Charles River Laboratories International, Inc. (Charles River) is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced preclinical services.
You May Also Be Interested In
- UPDATE: UBS Downgrades Avon Products (AVP) to Sell; Still Cautious Even After Sell Off
- Avondale Partners Downgrades Sun Healthcare Group (SUNH) to Market Perform
- Guggenheim Initiates Coverage on Several Oil & Gas Drilling & Exploration Stocks; Upgrades DO & ESV, Lowers RDC
Create E-mail Alert Related Categories
DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
